Sil Kordes

Hallmarks of cancer stem cell metabolism

Smarter drugs emerging in pancreatic cancer therapy

Metformin as a Tool to Target Aging

Cancer metabolism: a therapeutic perspective

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

Cancer stem cells revisited

The mechanisms of action of metformin

An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer

Understanding the Intersections between Metabolism and Cancer Biology

Targeting ferroptosis as a vulnerability in cancer

The PI3K Pathway in Human Disease

Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells

Research into cancer metabolomics: Towards a clinical metamorphosis

Obesity and Cancer Mechanisms: Cancer Metabolism

Is Mitochondrial Dysfunction a Common Root of Noncommunicable Chronic Diseases?

Fundamentals of cancer metabolism

The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies

Spermidine in health and disease

A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer

Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial

A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.